about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerRadioimmunotherapy of human tumoursProtein-protein fusion catalyzed by sortase AAn alternative chemical redox method for the production of bispecific antibodies: implication in rapid detection of food borne pathogensA novel redox method for rapid production of functional bi-specific antibodies for use in early pilot studiesAdvances in Antibody DesignCDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibodyEngineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicityPreclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complexComputational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Advancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipelineMolecular Magnetic Resonance Imaging of Tumor Response to Therapy.A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.Dual targeting strategies with bispecific antibodies.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.IgG Binding Characteristics of Rhesus Macaque FcγRProduction of bispecific antibodies in "knobs-into-holes" using a cell-free expression systemEfficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells.The making of bispecific antibodiesDetection of a phosphorylated glycine-serine linker in an IgG-based fusion protein.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.Highly parallel characterization of IgG Fc binding interactions.Cell-type specific potent Wnt signaling blockade by bispecific antibody.Bispecific antibodies in cancer immunotherapy.Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
P2860
Q26852215-4ED23430-F4F4-42A5-AB22-173C51127EAFQ28088825-EA526046-B716-4DF8-953D-7C0917E38DD6Q28477673-FA6CA5CA-969F-4F56-8C66-4BD3126FE7A6Q28540976-043125B1-F889-4A16-93E8-C6893EE505E0Q28742330-026307DB-7F56-4BB8-BC76-82104ACAC525Q28817608-764D2ADD-31EF-4657-9E23-66D1303D837AQ31135534-1C09BA6B-1AF4-4AEF-AFC1-00FF4DAB3FF0Q33649168-79BA31DD-043D-4B22-BD10-6073B7F7FEE5Q33661948-F4E58746-815D-49A2-9763-E2BA10136925Q34212771-9444593E-A298-4376-9B22-DB1A3244A1AFQ34456470-89178F46-9CB5-4001-90D5-AABD0CA05616Q34473476-732EBD5C-8EC0-4071-A312-5C525ECBDE3FQ35152029-E48FFC0D-028F-46CA-848C-F4140240071FQ35518032-DA2648E6-AE58-4D0B-974C-C9803D0819FBQ36123378-1163149F-1657-4A39-8700-417D321332C8Q36466175-0ED3983E-6582-498C-B447-DB22DF45B10AQ36610788-0E91CD6A-D648-4112-BA6F-6B5CD8C5D41CQ36746466-75E5B64C-3F28-42CF-B979-65D5AFED03E3Q37327316-0E4B6AF7-D9B6-4D78-BC1C-4A8829DD8547Q37656465-BC4FF1B2-E9B0-434B-8995-96496673346DQ37997559-69C03009-53E1-4156-A36D-67E841646ECEQ38074885-EE502ED4-9EE1-4F95-BBA4-545181EC3B54Q38674449-79C883B5-1FF3-4DA4-B64B-8ECAC2D236A5Q38707896-06E97C8F-3DE0-4A1E-824F-BE94C31CDFB5Q38790644-553E2979-4EB5-4767-8C6A-CD4177C9152AQ40608217-2CCF1707-68AF-4F1E-A5E8-B1F0AC92A6A0Q41647084-5601709A-6B29-4EDE-A2DE-B4396D29B36BQ41711395-B3A30A66-7978-4F52-A378-D5268EF1941CQ42323236-61DADF45-4E9A-4DDD-A634-635026C889E8Q42330118-E09CE07A-B547-489C-B3D5-3D03C9C32D9BQ42660142-606228D2-6871-4284-98A0-54428836DDF3Q42854245-2DF3DC3E-BA46-49A2-8E46-7C2265A3FD24Q42909129-083729F9-8B1A-4224-BAB6-48F040C86B29Q49292906-1B901E27-0628-4C73-AC98-F73FEE61088CQ51309023-07910482-FA1C-4425-B5F2-C6B3FAEC26A2Q59133661-44A8B875-9496-4E2E-80B4-FAAB54048299
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A modular IgG-scFv bispecific antibody topology.
@ast
A modular IgG-scFv bispecific antibody topology.
@en
A modular IgG-scFv bispecific antibody topology.
@nl
type
label
A modular IgG-scFv bispecific antibody topology.
@ast
A modular IgG-scFv bispecific antibody topology.
@en
A modular IgG-scFv bispecific antibody topology.
@nl
prefLabel
A modular IgG-scFv bispecific antibody topology.
@ast
A modular IgG-scFv bispecific antibody topology.
@en
A modular IgG-scFv bispecific antibody topology.
@nl
P2093
P2860
P356
P1476
A modular IgG-scFv bispecific antibody topology.
@en
P2093
Adrian L Slusarczyk
Emmanuel Quiroz
K Dane Wittrup
Kelly Davis Orcutt
Margaret E Ackerman
Maryelise Cieslewicz
P2860
P304
P356
10.1093/PROTEIN/GZP077
P577
2009-12-17T00:00:00Z